Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.52 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5757609 | 0.95 | ELANE (0.56) | ELANELMNATRPV4KMT2ADRD3 | |
| SCHEMBL5757603 | 0.85 | ELANE (0.57) | ELANETRPV4KMT2ADRD3 | |
| SCHEMBL5759549 | 0.85 | ELANE (0.57) | ELANEKMT2ASMN1; SMN2 | |
| SCHEMBL5759229 | 0.85 | ELANE (0.57) | ELANETRPV4KMT2ADRD3 | |
| SCHEMBL31490190 | 0.84 | TRPV4 (0.53) | ELANECD274TRPV4 | |
| SCHEMBL561336 | 0.84 | TRPV4 (0.53) | ELANECD274TRPV4 | |
| SCHEMBL4020499 | 0.84 | ELANE (0.49) | ELANEEPHX2CD274LMNATRPV4 | |
| SCHEMBL5760587 | 0.84 | ELANE (0.70) | ELANEKMT2APOLB | |
| SCHEMBL4126011 | 0.84 | BCL3 (0.55) | EPHX2CD274LMNAKMT2APOLB | |
| SCHEMBL5758317 | 0.83 | ELANE (0.59) | ELANEKMT2APOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | ELANE 2/4885EPHX2 435/4885CD274 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.